Despite global political uncertainties and a sluggish economic outlook for 2017, the global healthcare industry is set for an invigorating year, according to a new analysis from Frost & Sullivan. This outlook is due to a partial realization of major healthcare policies and initiatives, technology advancements and value-based care driving the adoption and need for consumer-centric targeted therapies. Future drugs and medical devices will be more targeted to meet the unique needs of emerging markets (e.g. China, India, Brazil) which demonstrate high growth opportunities compared developed markets (e.g., the United States and Western Europe. Growing at a CAGR of 4.8 percent, the industry is likely to reach revenue of $1,731.8 billion.

March 7, 2017 — Medtronic plc recently announced an economic analysis of five-year data showing that patients with mild ...

Philips and Phoenix Children’s Hospital (Arizona) announced a long-term strategic partnership with a total value of up to $65 million, providing the hospital access to Philips’ advanced medical technologies. Phoenix Children’s is the first stand-alone children’s health system to sign a long-term strategic partnership model with Philips.

March 6, 2017 — Logicalis Healthcare Solutions announced in February a new service desk offering – Service Desk for Epic ...

Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new BioFreedom Pivotal Study. The study will be conducted under an Investigational Device Exemption (IDE), which will include sites in the United States, Canada, Denmark, France Germany and Italy.

March 3, 2017 — In a United Kingdom patent case involving a Edwards Lifesciences lawsuit against Boston Scientific for ...

In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new positron emission tomography (PET) radiotracer, gallium-68 (Ga-68)-pentixafor, can quickly and non-invasively identify life-threatening atherosclerotic plaques. The tracer binds to the CXCR4 receptor on inflammatory cells present in atherosclerotic plaques — making it possible to find and treat atherosclerosis early.